The recent coronavirus disease (COVID-19), which was first reported in China, has spread around the world, causing major public health concerns. 1 Several treatments have been proposed for the treatment of COVID-19, including hydroxychloroquine, monoclonal antibodies, corticosteroids, favipiravir, lopinavir/ritonavir, anticoagulants, and azithromycin. 2 Here, we present a case of pustular psoriasis, exacerbated by COVID-19 in a patient with a history of hydroxychloroquine use. Patient consent for publication is achieved. The patient was a 47-year-old woman, presenting with pustular lesions over the past 3 weeks. The COVID-19 symptoms, including sore throat, myalgia, fever, and dry cough (for 8 days), had developed over the past 6 weeks. The chest computed tomography (CT) scan showed bilateral peripheral ground-glass opacities and infiltrations. Oxygen saturation was in the normal range. She was tested for

Neurological diseases in general, and stroke and dementia in particular, were significantly associated with bullous pemphigoid in our study.

No abstract